Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

por Manack Adams, Aubrey, Hutchinson, Susan, Engstrom, Ella, Ayasse, Nicolai D., Serrano, Daniel, Davis, Linda, Sommer, Katherine, Contreras-De Lama, Janette, Lipton, Richard B.
Publicado 2023

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine:...

por Jakate, Abhijeet, Blumenfeld, Andrew M., Boinpally, Ramesh, Butler, Matthew, Borbridge, Lisa, Contreras‐De Lama, Janette, McGeeney, Danielle, Periclou, Antonia, Lipton, Richard B.
Publicado 2021

Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study

por Lipton, Richard B., Lanteri-Minet, Michel, Leroux, Elizabeth, Manack Adams, Aubrey, Contreras-De Lama, Janette, Reed, Michael L., Fanning, Kristina M., Buse, Dawn C.
Publicado 2023